无糖尿病者遗传代理平均血糖与冠心病发病的剂量反应关系
研究利用UK Biobank中324830名无糖尿病的欧洲裔个体,以40个与2型糖尿病及HbA1c相关的遗传变异预测HbA1c,采用线性和非线性孟德尔随机化分析其与冠心病发病的关联。结果显示遗传代理HbA1c每增加1 mmol/mol,冠心病风险增加11%(HR 1.11,95%CI 1.05–1.18),剂量反应曲线在各HbA1c水平均上升,无证据支持非线性关系。结论提示在无糖尿病人群中降低平均血糖可能以剂量依赖方式降低冠心病风险。
要点
- 无糖尿病人群中遗传代理HbA1c每升高1 mmol/mol,冠心病风险增加11%。
- 剂量反应曲线在各HbA1c水平均上升,线性模型优于非线性模型。
- 降低平均血糖可能以剂量依赖方式降低冠心病风险。
核心结论
- 在无糖尿病人群中,降低平均血糖水平可能以剂量依赖方式降低冠心病风险。
研究设计与样本
- 研究纳入UK Biobank中324830名无糖尿病的欧洲裔个体,采用40个与2型糖尿病和HbA1c相关的遗传变异预测HbA1c,进行线性和非线性孟德尔随机化分析。
主要发现
- 遗传代理HbA1c每增加1 mmol/mol,冠心病风险增加11%(HR 1.11,95%CI 1.05–1.18)。
- 剂量反应曲线在各HbA1c水平均上升,无证据支持非线性关系优于线性关系。
临床怎么用
- 在无糖尿病人群中,评估平均血糖水平可能有助于识别冠心病风险,但降低血糖的干预策略需进一步研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Our aim was to investigate the relationship between average blood glucose levels and incident CHD in individuals without diabetes mellitus. METHODS: To investigate average blood glucose levels, we studied HbA1c as predicted by 40 variants previously shown to be associated with both type 2 diabetes and HbA1c. Linear and non-linear Mendelian randomisation analyses were performed to investigate associations with incident CHD risk in 324,830 European ancestry individuals from the UK Biobank without diabetes mellitus. RESULTS: Every one mmol/mol increase in genetically proxied HbA1c was associated with an 11% higher CHD risk (HR 1.11, 95% CI 1.05, 1.18). The dose-response curve increased at all levels of HbA1c, and there was no evidence favouring a non-linear relationship over a linear one. CONCLUSIONS/INTERPRETATIONS: In individuals without diabetes mellitus, lowering average blood glucose levels may reduce CHD risk in a dose-dependent way.
引用
- Burgess S, Malik R, Liu B, et al. Dose-response relationship between genetically proxied average blood glucose levels and incident coronary heart disease in individuals without diabetes mellitus. Diabetologia. 2021. PMID: 33495845. doi:10.1007/s00125-020-05377-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。